On July 9, 2026, FDA approved isatuximab-irfc (Sarclisa Escena, Sanofi Aventis) for subcutaneous injection in multiple myeloma, extending to all currently approved IV isatuximab indications: In ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
OncoDaily Grand Rounds at ESMO 2026: Key Discussions and Clinical Perspectives on Bladder Cancer, Part 1 ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
OptiTROP-Lung04 (NCT05870319), a pivotal phase 3 trial presented by Prof. Li Zhang (Guangzhou, China) at the ESMO Congress 2025, evaluated the efficacy and safety of the novel TROP2-directed ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...
Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg ...
Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research / ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results